RAPT Therapeutics (RAPT) Stock Forecast, Price Target & Predictions
RAPT Stock Forecast
RAPT Therapeutics stock forecast is as follows: an average price target of $42.20 (represents a 2064.10% upside from RAPT’s last price of $1.95) and a rating consensus of 'Hold', based on 7 wall street analysts offering a 1-year stock forecast.
RAPT Price Target
RAPT Analyst Ratings
RAPT Therapeutics Price Target by Analyst
Date | Analyst | Company | Price Target | Price when Published | Price Target/Price when Published | Price Target/Last Closing Price |
---|---|---|---|---|---|---|
Jan 04, 2023 | - | Guggenheim | $55.00 | $19.82 | 177.43% | 2720.51% |
Jan 04, 2023 | - | Wells Fargo | $48.00 | $19.50 | 146.15% | 2361.54% |
Dec 08, 2022 | Edward Tenthoff | Piper Sandler | $33.00 | $16.48 | 100.24% | 1592.31% |
Dec 01, 2022 | - | Goldman Sachs | $27.00 | $17.68 | 52.71% | 1284.62% |
Nov 11, 2022 | - | Piper Sandler | $34.00 | $21.98 | 54.69% | 1643.59% |
Sep 21, 2022 | Zegbeh Jallah | Capital One Financial | $48.00 | $24.17 | 98.59% | 2361.54% |
RAPT Therapeutics Price Target by Period
1M | 3M | 12M | |
---|---|---|---|
# Anlaysts | - | - | - |
Avg Price Target | - | - | - |
Last Closing Price | $1.95 | $1.95 | $1.95 |
Upside/Downside | -100.00% | -100.00% | -100.00% |
Analyst Ratings Upgrades/Downgrades
Date | Company | Previous Rating | New Rating | Rating Change |
---|---|---|---|---|
Aug 11, 2024 | Wells Fargo | Overweight | Overweight | Hold |
May 14, 2024 | Wolfe Research | - | Peer Perform | Downgrade |
May 10, 2024 | Barclays | Overweight | Equal-Weight | Downgrade |
May 09, 2024 | Guggenheim | Buy | Neutral | Downgrade |
May 09, 2024 | Guggenheim | Buy | Hold | Downgrade |
Feb 21, 2024 | Barclays | Overweight | Overweight | Hold |
Feb 21, 2024 | Cantor Fitzgerald | - | Neutral | Downgrade |
Feb 21, 2024 | Leerink Partners | - | Market Perform | Downgrade |
Jan 04, 2023 | Guggenheim | - | Buy | Initialise |
Jan 04, 2023 | Wells Fargo | Overweight | Overweight | Hold |
RAPT Therapeutics Financial Forecast
RAPT Therapeutics Revenue Forecast
Dec 26 | Sep 26 | Jun 26 | Mar 26 | Dec 25 | Sep 25 | Jun 25 | Mar 25 | Dec 24 | Sep 24 | Jun 24 | Dec 22 | Sep 22 | Jun 22 | Mar 22 | Dec 21 | Sep 21 | Jun 21 | Mar 21 | Dec 20 | Sep 20 | Jun 20 | Mar 20 | |
---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
Revenue | - | - | - | - | - | - | - | - | - | - | - | $641.00K | - | $886.00K | $641.00K | $756.00K | $966.00K | $869.00K | $1.22M | $1.30M | $1.53M | $1.28M | $935.00K |
Avg Forecast | - | - | - | - | - | - | - | - | - | - | - | $132.50K | $336.57K | $280.00K | $233.33K | $811.00K | $778.17K | $1.01M | $908.00K | $1.28M | $1.00M | $833.33K | $1.25M |
High Forecast | - | - | - | - | - | - | - | - | - | - | - | $132.50K | $336.57K | $280.00K | $233.33K | $811.00K | $778.17K | $1.01M | $908.00K | $1.28M | $1.00M | $833.33K | $1.25M |
Low Forecast | - | - | - | - | - | - | - | - | - | - | - | $132.50K | $336.57K | $280.00K | $233.33K | $811.00K | $778.17K | $1.01M | $908.00K | $1.28M | $1.00M | $833.33K | $1.25M |
# Analysts | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - |
Surprise % | - | - | - | - | - | - | - | - | - | - | - | 4.84% | - | 3.16% | 2.75% | 0.93% | 1.24% | 0.86% | 1.35% | 1.02% | 1.53% | 1.53% | 0.75% |
RAPT Therapeutics EBITDA Forecast
Dec 26 | Sep 26 | Jun 26 | Mar 26 | Dec 25 | Sep 25 | Jun 25 | Mar 25 | Dec 24 | Sep 24 | Jun 24 | Dec 22 | Sep 22 | Jun 22 | Mar 22 | Dec 21 | Sep 21 | Jun 21 | Mar 21 | Dec 20 | Sep 20 | Jun 20 | Mar 20 | |
---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
# Analysts | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - |
EBITDA | - | - | - | - | - | - | - | - | - | - | - | $-24.43M | $-21.42M | $-18.64M | $-20.52M | $-17.70M | $-18.42M | $-15.85M | $-16.23M | $451.26K | $-14.08M | $-11.72M | $-12.70M |
Avg Forecast | - | - | - | - | - | - | - | - | - | - | - | $-26.50K | $-16.36M | $-56.00K | $-19.91M | $-162.20K | $-155.63K | $-202.50K | $-15.19M | $-255.28K | $-200.15K | $-166.67K | $-8.86M |
High Forecast | - | - | - | - | - | - | - | - | - | - | - | $-26.50K | $-13.09M | $-56.00K | $-15.93M | $-162.20K | $-155.63K | $-202.50K | $-12.15M | $-255.28K | $-200.15K | $-166.67K | $-7.09M |
Low Forecast | - | - | - | - | - | - | - | - | - | - | - | $-26.50K | $-19.64M | $-56.00K | $-23.89M | $-162.20K | $-155.63K | $-202.50K | $-18.22M | $-255.28K | $-200.15K | $-166.67K | $-10.64M |
Surprise % | - | - | - | - | - | - | - | - | - | - | - | 921.96% | 1.31% | 332.77% | 1.03% | 109.11% | 118.37% | 78.29% | 1.07% | -1.77% | 70.35% | 70.34% | 1.43% |
RAPT Therapeutics Net Income Forecast
Dec 26 | Sep 26 | Jun 26 | Mar 26 | Dec 25 | Sep 25 | Jun 25 | Mar 25 | Dec 24 | Sep 24 | Jun 24 | Dec 22 | Sep 22 | Jun 22 | Mar 22 | Dec 21 | Sep 21 | Jun 21 | Mar 21 | Dec 20 | Sep 20 | Jun 20 | Mar 20 | |
---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
# Analysts | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - |
Net Income | - | - | - | - | - | - | - | - | - | - | - | $-21.47M | $-20.79M | $-19.46M | $-20.16M | $-17.93M | $-18.65M | $-16.11M | $-16.51M | $-12.73K | $-14.63M | $-12.39M | $-13.14M |
Avg Forecast | $-21.26M | $-21.41M | $-19.60M | $-19.76M | $-18.21M | $-19.40M | $-20.61M | $-20.31M | $-18.08M | $-21.94M | $-28.00M | $-25.43M | $-16.57M | $-28.73M | $-20.17M | $-25.70M | $-24.20M | $-26.41M | $-15.45M | $-22.54M | $-21.84M | $-22.99M | $-9.17M |
High Forecast | $-21.26M | $-21.41M | $-19.60M | $-19.76M | $-18.21M | $-19.40M | $-20.61M | $-20.31M | $-18.08M | $-17.63M | $-28.00M | $-25.43M | $-13.25M | $-28.73M | $-16.13M | $-25.70M | $-24.20M | $-26.41M | $-12.36M | $-22.54M | $-21.84M | $-22.99M | $-7.33M |
Low Forecast | $-21.26M | $-21.41M | $-19.60M | $-19.76M | $-18.21M | $-19.40M | $-20.61M | $-20.31M | $-18.08M | $-25.07M | $-28.00M | $-25.43M | $-19.88M | $-28.73M | $-24.20M | $-25.70M | $-24.20M | $-26.41M | $-18.54M | $-22.54M | $-21.84M | $-22.99M | $-11.00M |
Surprise % | - | - | - | - | - | - | - | - | - | - | - | 0.84% | 1.26% | 0.68% | 1.00% | 0.70% | 0.77% | 0.61% | 1.07% | 0.00% | 0.67% | 0.54% | 1.43% |
RAPT Therapeutics SG&A Forecast
Dec 26 | Sep 26 | Jun 26 | Mar 26 | Dec 25 | Sep 25 | Jun 25 | Mar 25 | Dec 24 | Sep 24 | Jun 24 | Dec 22 | Sep 22 | Jun 22 | Mar 22 | Dec 21 | Sep 21 | Jun 21 | Mar 21 | Dec 20 | Sep 20 | Jun 20 | Mar 20 | |
---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
# Analysts | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - |
SG&A | - | - | - | - | - | - | - | - | - | - | - | $4.98M | $5.08M | $5.44M | $4.75M | $4.49M | $3.77M | $3.76M | $4.01M | $3.48M | $3.20M | $2.80M | $3.29M |
Avg Forecast | - | - | - | - | - | - | - | - | - | - | - | $582.83K | $1.48M | $1.23M | $1.03M | $3.57M | $3.42M | $4.45M | $3.99M | $5.61M | $4.40M | $3.67M | $5.50M |
High Forecast | - | - | - | - | - | - | - | - | - | - | - | $582.83K | $1.48M | $1.23M | $1.03M | $3.57M | $3.42M | $4.45M | $3.99M | $5.61M | $4.40M | $3.67M | $5.50M |
Low Forecast | - | - | - | - | - | - | - | - | - | - | - | $582.83K | $1.48M | $1.23M | $1.03M | $3.57M | $3.42M | $4.45M | $3.99M | $5.61M | $4.40M | $3.67M | $5.50M |
Surprise % | - | - | - | - | - | - | - | - | - | - | - | 8.54% | 3.43% | 4.41% | 4.63% | 1.26% | 1.10% | 0.84% | 1.00% | 0.62% | 0.73% | 0.76% | 0.60% |
RAPT Therapeutics EPS Forecast
Dec 26 | Sep 26 | Jun 26 | Mar 26 | Dec 25 | Sep 25 | Jun 25 | Mar 25 | Dec 24 | Sep 24 | Jun 24 | Dec 22 | Sep 22 | Jun 22 | Mar 22 | Dec 21 | Sep 21 | Jun 21 | Mar 21 | Dec 20 | Sep 20 | Jun 20 | Mar 20 | |
---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
# Analysts | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - |
EPS | - | - | - | - | - | - | - | - | - | - | - | $-0.60 | $-0.62 | $-0.62 | $-0.68 | $-0.61 | $-0.63 | $-0.63 | $-0.66 | $-0.00 | $-0.60 | $-0.51 | $-0.56 |
Avg Forecast | $-0.55 | $-0.55 | $-0.50 | $-0.51 | $-0.47 | $-0.50 | $-0.53 | $-0.52 | $-0.47 | $-0.56 | $-0.72 | $-0.65 | $-0.67 | $-0.74 | $-0.68 | $-0.66 | $-0.62 | $-0.68 | $-0.60 | $-0.58 | $-0.56 | $-0.59 | $-0.49 |
High Forecast | $-0.55 | $-0.55 | $-0.50 | $-0.51 | $-0.47 | $-0.50 | $-0.53 | $-0.52 | $-0.47 | $-0.45 | $-0.72 | $-0.65 | $-0.67 | $-0.74 | $-0.68 | $-0.66 | $-0.62 | $-0.68 | $-0.60 | $-0.58 | $-0.56 | $-0.59 | $-0.49 |
Low Forecast | $-0.55 | $-0.55 | $-0.50 | $-0.51 | $-0.47 | $-0.50 | $-0.53 | $-0.52 | $-0.47 | $-0.65 | $-0.72 | $-0.65 | $-0.67 | $-0.74 | $-0.68 | $-0.66 | $-0.62 | $-0.68 | $-0.60 | $-0.58 | $-0.56 | $-0.59 | $-0.49 |
Surprise % | - | - | - | - | - | - | - | - | - | - | - | 0.92% | 0.92% | 0.84% | 1.00% | 0.92% | 1.01% | 0.93% | 1.10% | 0.00% | 1.07% | 0.86% | 1.14% |
RAPT Therapeutics Peer Comparison by Price Target
Ticker | Company | Last Closing Price | Avg Price Target | Upside/Downside | Avg Rating |
---|---|---|---|---|---|
RAPT | RAPT Therapeutics | $1.95 | $42.20 | 2064.10% | Hold |
PMVP | PMV Pharmaceuticals | $1.51 | $24.75 | 1539.07% | Buy |
XLO | Xilio Therapeutics | $0.82 | $7.00 | 753.66% | Buy |
ANTX | AN2 Therapeutics | $1.04 | $8.75 | 741.35% | Buy |
MOLN | Molecular Partners | $5.22 | $29.00 | 455.56% | Buy |
HOWL | Werewolf Therapeutics | $2.34 | $12.00 | 412.82% | Buy |
PLRX | Pliant Therapeutics | $12.00 | $39.71 | 230.92% | Buy |
PEPG | PepGen | $9.48 | $29.50 | 211.18% | Buy |
ARVN | Arvinas | $25.05 | $75.36 | 200.84% | Buy |
ANEB | Anebulo Pharmaceuticals | $2.08 | $6.00 | 188.46% | Buy |
RLAY | Relay Therapeutics | $7.60 | $19.50 | 156.58% | Buy |
MLYS | Mineralys Therapeutics | $11.76 | $30.00 | 155.10% | Buy |
BDTX | Black Diamond Therapeutics | $6.19 | $14.75 | 138.29% | Buy |
STOK | Stoke Therapeutics | $14.47 | $33.75 | 133.24% | Buy |
PHVS | Pharvaris | $20.92 | $38.50 | 84.03% | Buy |
DSGN | Design Therapeutics | $5.54 | $9.67 | 74.55% | Buy |
ELYM | Eliem Therapeutics | $8.46 | $13.00 | 53.66% | Buy |
CNTB | Connect Biopharma | $1.23 | $1.50 | 21.95% | Buy |
TYRA | Tyra Biosciences | $21.24 | $25.00 | 17.70% | Buy |
IKNA | Ikena Oncology | $1.69 | $1.33 | -21.30% | Buy |
RAPT Forecast FAQ
Is RAPT Therapeutics a good buy?
No, according to 7 Wall Street analysts, RAPT Therapeutics (RAPT) is considered a 'Hold'. The rating consensus is based on 0 'Strong Buy' and 3 'Buy' recommendations, accounting for 42.86% of RAPT's total ratings.
What is RAPT's price target?
RAPT Therapeutics (RAPT) average price target is $42.2 with a range of $27 to $55, implying a 2064.10% from its last price of $1.95. The data is based on 7 Wall Street analysts who provided a twelve-month price target estimate in the last three months.
Will RAPT Therapeutics stock go up soon?
According to Wall Street analysts' prediction for RAPT stock, the company can go up by 2064.10% (from the last price of $1.95 to the average price target of $42.2), up by 2720.51% based on the highest stock price target, and up by 1284.62% based on the lowest stock price target.
Can RAPT Therapeutics stock reach $3?
RAPT's average twelve months analyst stock price target of $42.2 supports the claim that RAPT Therapeutics can reach $3 in the near future.
What are RAPT Therapeutics's analysts' financial forecasts?
RAPT Therapeutics's analysts financial forecasts for the fiscal year (Dec 2025) are as follows: average revenue is $0 (high $0, low $0), average EBITDA is $0 (high $0, low $0), average net income is $-78.532M (high $-78.532M, low $-78.532M), average SG&A $0 (high $0, low $0), and average EPS is $-2.021 (high $-2.021, low $-2.021). RAPT's analysts financial forecasts for the fiscal year (Dec 2026) are as follows: average revenue is $0 (high $0, low $0), average EBITDA is $0 (high $0, low $0), average net income is $-82.032M (high $-82.032M, low $-82.032M), average SG&A $0 (high $0, low $0), and average EPS is $-2.111 (high $-2.111, low $-2.111).
Did the RAPT's actual financial results beat the analysts' financial forecasts?
Based on RAPT Therapeutics's last annual report (Dec 2022), the company's revenue was $1.53M, beating the average analysts forecast of $982.4K by 55.44%. Apple's EBITDA was $-85.795M, beating the average prediction of $-36.356M by 135.99%. The company's net income was $-81.881M, missing the average estimation of $-90.897M by -9.92%. Apple's SG&A was $20.24M, beating the average forecast of $4.32M by 368.38%. Lastly, the company's EPS was $-2.52, missing the average prediction of $-2.743 by -8.14%. In terms of the last quarterly report (Dec 2022), RAPT Therapeutics's revenue was $641K, beating the average analysts' forecast of $132.5K by 383.77%. The company's EBITDA was $-24.431M, beating the average prediction of $-26.499K by 92095.93%. RAPT Therapeutics's net income was $-21.471M, missing the average estimation of $-25.429M by -15.56%. The company's SG&A was $4.98M, beating the average forecast of $582.83K by 753.94%. Lastly, the company's EPS was $-0.6, missing the average prediction of $-0.654 by -8.29%